Selecting and Designing Diabetes Research Topics: Gut Microbiota Diversity and Abundance in Relation to Glycated Haemoglobin and Insulin Resistance in Type 2 Diabetes

Selecting and Designing Diabetes Research Topics: Gut Microbiota Diversity and Abundance in Relation to Glycated Haemoglobin and Insulin Resistance in Type 2 Diabetes

Best for: Endocrinologists and postgraduate supervisors; clinicians and statisticians designing diabetes studies; gastroenterologists and gut microbiome researchers; laboratory medicine and bioinformatics analysts; nursing and chronic disease management researchers; clinical research methodologists and medical editors; clinicians preparing grant applications or dissertations. Primary keywords: type 2 diabetes; gut microbiota; 16S rRNA gene sequencing; glycated haemoglobin; HOMA-IR; insulin resistance; gut-pancreas axis; short-chain fatty acids; butyrate-producing bacteria; metabolic endotoxaemia; multiple linear regression; research topic selection

Short Answer

In diabetes research, a topic succeeds or fails on whether the question can be quantified, whether confounders can be controlled, and whether the boundary of the conclusion can be stated. This article presents the full design skeleton of one clinical topic, the association of gut microbiota diversity and abundance with glycated haemoglobin and the homeostatic model assessment of insulin resistance in type 2 diabetes. The study used a cross-sectional case-control design, enrolling patients with type 2 diabetes and healthy controls frequency-matched for age, sex and body mass index, measuring fasting plasma glucose, fasting insulin and glycated haemoglobin to derive HOMA-IR, and performing high-throughput sequencing of the V3-V4 region of the 16S rRNA gene on stool samples. The type 2 diabetes group showed significantly lower Shannon and Chao1 indices than controls, with Cohen d of 0.68 and 0.71 respectively, and principal coordinate analysis on weighted UniFrac distances showed significant separation of community structure (PERMANOVA, R squared 0.12, P=0.001). At genus level the butyrate producers Faecalibacterium and Roseburia were significantly depleted while the opportunistic pathogen Escherichia-Shigella was enriched. Spearman analysis showed Faecalibacterium abundance negatively correlated with glycated haemoglobin (r minus 0.45, P below 0.001) and with HOMA-IR (r minus 0.40, P below 0.001), while Escherichia-Shigella correlated positively with glycated haemoglobin (r 0.42, P below 0.001). After adjustment for age, body mass index and disease duration, multiple linear regression confirmed Faecalibacterium as an independent determinant of glycated haemoglobin (beta minus 0.32, P=0.002) and of HOMA-IR (beta minus 0.29, P=0.005), with adjusted R squared of 0.35 and 0.30. The value of this topic lies in compressing the broad claim of dysbiosis into a quantified, stratifiable and intervenable association.

1. Topic Selection Logic: Where High-Value Questions Come From

1.1 Identifying a genuine clinical gap from disease burden

Type 2 diabetes has become one of the most serious public health challenges worldwide, with patient numbers rising steadily in step with lifestyle transition and socioeconomic development. In China, accelerating urbanisation has pushed overweight and obesity rates to 30.0 percent and 12.3 percent, moving in parallel with diabetes incidence. Type 2 diabetes is fundamentally a metabolic disease characterised by chronic hyperglycaemia resulting from defective insulin secretion, defective insulin action, or both, and its core pathophysiological abnormality is a vicious cycle of insulin resistance and beta-cell failure. About 50 percent of newly diagnosed patients already show significant beta-cell failure, while insulin resistance, the initiating driver, rises steeply with the obesity epidemic. Sustained hyperglycaemia causes multi-system damage, markedly reducing quality of life and increasing mortality, so the search for new intervention targets answers a pressing clinical need. In practice, genuine gaps appear in two zones: problems already known to matter but mechanistically unresolved, and markers already measurable but lacking agreed thresholds. Describing a wholly new disease is rarely one of them.

1.2 The gut-pancreas axis: a cut with both mechanistic depth and measurability

The gut microbiota has drawn wide attention as a virtual organ regulating host metabolism, participating in energy metabolism, immune regulation and insulin sensitivity through multiple mechanisms. Gut microorganisms encode carbohydrate-active enzymes that break down dietary fibre the host cannot digest, releasing short-chain fatty acids including butyrate, propionate and acetate. Butyrate is not only the principal energy source for colonic epithelial cells but also promotes regulatory T cell differentiation to exert anti-inflammatory effects, and acts directly on pancreatic beta cells and adipose tissue to improve insulin sensitivity. Dysbiosis, by contrast, damages the intestinal barrier and increases permeability, allowing lipopolysaccharide to enter the circulation and induce metabolic endotoxaemia, which activates chronic low-grade inflammation through the Toll-like receptor 4 pathway and aggravates insulin resistance. The microbiota also participates in host metabolic homeostasis by modulating bile acid metabolism, influencing vitamin synthesis and producing signalling molecules. Together these mechanisms form the gut-pancreas axis hypothesis, whose advantage as a research topic is that every step has a detectable intermediate and a quantifiable endpoint.

1.3 Existing gaps and the question this study answers

Although numerous animal and cross-sectional studies confirm dysbiosis in type 2 diabetes, three gaps remain. First, previous work concentrated on animal models or small exploratory samples, leaving a shortage of quantified association studies between microbiota characteristics and core clinical indicators such as glycated haemoglobin and HOMA-IR in larger Chinese populations. Second, findings on the relationship between diversity and glycaemic control are inconsistent: some studies report negative correlations between alpha diversity and glycaemic control while others find none, a contradiction plausibly arising from inadequate adjustment for dietary pattern, medication history, especially metformin, and body mass index. Third, although butyrate producers are thought to improve insulin sensitivity, direct evidence from multivariable regression that specific genera act independently of conventional risk factors such as age, body mass index and disease duration is lacking. In addition, the substantial effects of agents such as acarbose and vildagliptin on microbiota composition, and the finding that metformin exerts part of its glucose-lowering effect by altering microbiota structure, mean that medication history must be rigorously adjusted. The question can therefore be framed as follows: do patients with type 2 diabetes show characteristic dysbiosis, and does that dysbiosis remain independently associated with glycaemic control and insulin resistance after conventional risk factors are controlled.

2. Study Design: PICOS and Implementation Points for a Cross-Sectional Case-Control Study

2.1 Participants and eligibility criteria

The study used a cross-sectional case-control design, recruiting consecutive participants from an endocrinology outpatient clinic and a health examination centre, with protocol approval from the ethics committee and written informed consent from all participants. Inclusion criteria for the type 2 diabetes group were: meeting the 1999 World Health Organization or current American Diabetes Association diagnostic criteria for type 2 diabetes; age 18 to 75 years; body mass index between 18.5 and 28 kg per square metre to exclude the confounding effect of severe obesity on microbiota; glycated haemoglobin between 6.5 and 11.0 percent to ensure a clear gradient in glycaemic control; and no glucose-lowering medication for at least three months before enrolment, or stable metformin monotherapy at 1000 mg per day or more for at least three months, to control the medication effect on microbiota. Healthy controls were frequency-matched for age, sex and geographic region, with the same body mass index range, fasting plasma glucose below 6.1 mmol/L, no history of diabetes and no history of metabolic disease, chronic inflammatory disease or malignancy. Both groups were excluded for: use of antibiotics, probiotics, prebiotics, synbiotics or systemic glucocorticoids within four weeks before enrolment; inflammatory bowel disease, irritable bowel syndrome, chronic diarrhoea or constipation, or gastrointestinal surgery; type 1 diabetes, diabetic ketoacidosis, diabetic gastroparesis, thyroid dysfunction, Cushing syndrome, severe hepatic or renal insufficiency, malignancy, immunodeficiency or psychiatric illness; strict weight-reduction diets, vegetarian or vegan diets within three months before enrolment; and pregnancy or lactation.

2.2 Data and sample collection workflow

Implementation proceeded in five steps. Step one, demographic information, lifestyle factors including smoking and alcohol use, medical history, medication history covering glucose-lowering, antihypertensive and lipid-lowering agents, and diabetes duration were collected by standardised questionnaire, with height and weight measured to derive body mass index. Step two, after at least ten hours of fasting, antecubital venous blood was collected in the early morning; fasting plasma glucose was measured by the glucose oxidase method, glycated haemoglobin by high-performance liquid chromatography and fasting insulin by chemiluminescence, with the homeostatic model assessment of insulin resistance calculated as fasting insulin in mU/L multiplied by fasting plasma glucose in mmol/L divided by 22.5; all assays were performed in the central laboratory with intra-assay and inter-assay coefficients of variation controlled within 10 and 15 percent. Step three, participants were instructed to collect fresh mid-stream stool in a sterile tube containing DNA stabilising solution on the morning of blood collection or the previous evening; samples were frozen at minus 20 degrees C immediately and transferred to minus 80 degrees C within 24 hours, then total genomic DNA was extracted with a commercial stool DNA kit and quality-checked by agarose gel electrophoresis and spectrophotometry, requiring an OD260/280 ratio between 1.8 and 2.0 and a concentration of at least 20 ng per microlitre. Step four, the V3-V4 hypervariable region of the 16S rRNA gene was amplified with universal primers 338F and 806R, and purified and quantified products underwent paired-end high-throughput sequencing. Step five, raw data were assembled, quality-controlled and denoised to generate amplicon sequence variants, annotated against a reference database, and then analysed for diversity and differential taxa.

2.3 Bioinformatics and statistical methods

Bioinformatic analysis covered three levels. Alpha diversity assessed within-sample richness and evenness using the Shannon index, Chao1 index, observed amplicon sequence variants and Simpson index. Beta diversity used principal coordinate analysis based on weighted UniFrac distances, with permutational multivariate analysis of variance over 999 permutations to test between-group structural differences. Differential taxa were identified by linear discriminant analysis effect size at phylum and genus level. Statistical analysis used standard statistical software and the R environment. Continuous variables were first tested for normality: normally distributed variables were expressed as mean with standard deviation and compared by independent-samples t test, and non-normally distributed variables as median with interquartile range and compared by Mann-Whitney U test. Categorical variables were expressed as counts with percentages and compared by chi-square or Fisher exact test. To assess associations between microbiota characteristics and clinical indicators, Spearman rank correlation was used for univariate exploration, followed by multiple linear regression with glycated haemoglobin or HOMA-IR as the dependent variable, significantly correlated genera as independent variables, and age, sex, body mass index, diabetes duration and metformin use forced into the model as covariates. All tests were two-sided with P below 0.05 taken as statistically significant.

2.4 Design elements at a glance

3. Result Framework and Core Findings

3.1 Baseline characteristics and metabolic differences

The two groups were matched for age, sex composition and body mass index to control these known determinants of microbiota. Compared with healthy controls, the type 2 diabetes group showed significantly higher fasting plasma glucose, glycated haemoglobin and HOMA-IR (P below 0.01), while fasting insulin did not differ significantly (P above 0.05), indicating a hyperglycaemic state dominated by insulin resistance. The baseline comparison table is the first credibility anchor in studies of this type: if matching fails or metabolic differences are not significant, later association analyses lose their interpretive space.

3.2 Alpha and beta diversity

Alpha diversity results showed that Shannon and Chao1 indices were significantly lower in the type 2 diabetes group than in healthy controls (P below 0.05). The mean Shannon index fell by about 0.24 (Cohen d 0.68), indicating reduced evenness, and the mean Chao1 index fell by about 36 (Cohen d 0.71), indicating significantly reduced richness. Notably, some studies have found no statistically significant difference in alpha diversity among rigorously matched participants, which may relate to sample size, population background and medication history. In this study, although metformin use may influence diversity, the between-group difference remained statistically significant after that factor was controlled, suggesting that type 2 diabetes itself is the principal driver of reduced diversity. For beta diversity, principal coordinate analysis based on weighted UniFrac distances showed significant spatial separation of community structure between groups (PERMANOVA, R squared 0.12, P=0.001). Further analysis found that age, body mass index and total cholesterol had little influence on clustering, with no independent subgroups formed by these factors; the separation also persisted in the subgroup not receiving medication, suggesting that dysbiosis occurs early in the disease course.

3.3 Compositional differences at phylum and genus level

At phylum level both groups were dominated by Firmicutes and Bacteroidetes, which together accounted for 80 to 90 percent of total bacteria. The type 2 diabetes group showed a distinct dysbiotic pattern: Firmicutes abundance rose while Bacteroidetes fell, so the Firmicutes to Bacteroidetes ratio was significantly higher than in controls (P below 0.05). This trend matches several previous studies and suggests the ratio may be a signature feature of dysbiosis in type 2 diabetes, closely linked to disturbed host energy metabolism; Proteobacteria, which includes several opportunistic pathogens, also trended upward, a shift often associated with intestinal inflammation and endotoxaemia. At genus level, linear discriminant analysis effect size identified multiple significant differences. Several genera known to produce short-chain fatty acids, particularly butyrate, were significantly depleted, with Faecalibacterium and Roseburia most prominent. Faecalibacterium prausnitzii is among the most important butyrate producers in the gut, and its depletion is linked to impaired barrier function and reduced anti-inflammatory capacity. Roseburia is likewise a key butyrate producer whose decline weakens energy supply to intestinal epithelial cells and increases permeability. Bifidobacterium also trended downward. Conversely, Escherichia-Shigella was the most significantly enriched genus; as a Gram-negative organism, its cell wall lipopolysaccharide is a key driver of metabolic endotoxaemia and chronic low-grade inflammation and can directly aggravate insulin resistance. Certain Clostridium species also trended upward, potentially exacerbating dysbiosis by competitively inhibiting butyrate producers and altering luminal pH, thereby closing a vicious circle.

3.4 Correlation analysis and independent determinants

To quantify the relationship between microbiota characteristics and glycaemic control and insulin resistance, the study applied Spearman correlation to key differential genera. For glycated haemoglobin, Faecalibacterium abundance correlated negatively (r minus 0.45, P below 0.001), Roseburia negatively (r minus 0.38, P below 0.01) and Escherichia-Shigella positively (r 0.42, P below 0.001). For HOMA-IR, Faecalibacterium correlated negatively (r minus 0.40, P below 0.001), Roseburia negatively (r minus 0.35, P below 0.01) and Escherichia-Shigella positively (r 0.39, P below 0.001). These correlations held in both healthy participants and patients with type 2 diabetes, supporting a key role for the balance between butyrate producers and opportunistic pathogens in regulating host insulin sensitivity. To exclude confounding by age, sex, body mass index and disease duration, the study then built multiple linear regression models. After adjustment, Faecalibacterium abundance (beta minus 0.32, P=0.002) and Escherichia-Shigella abundance (beta 0.28, P=0.01) remained independent determinants of glycated haemoglobin, with the model explaining about 35 percent of its variance (adjusted R squared 0.35); Faecalibacterium abundance (beta minus 0.29, P=0.005) and Escherichia-Shigella abundance (beta 0.25, P=0.02) were likewise independent determinants of HOMA-IR, with about 30 percent explained (adjusted R squared 0.30). Roseburia was significant in univariate analysis but lost independent contribution in multivariable regression (P above 0.05), plausibly because Roseburia and Faecalibacterium, both butyrate producers with closely coordinated function, are collinear. That is a finding to state and interpret in the discussion rather than to omit.

3.5 Effect size overview

4. Mechanistic Chain: From Butyrate Deficiency to Insulin Resistance

4.1 Short-chain fatty acid theory and endotoxin inflammation acting together

The finding that butyrate-producing genera are depleted and negatively correlated with HOMA-IR is consistent with mainstream evidence and can be explained by the combined action of short-chain fatty acid theory and endotoxin inflammation theory. First, butyrate producers are the principal source of colonic butyrate, and butyrate is the main energy substrate for intestinal epithelial cells and is essential for barrier integrity. When these genera decline, luminal butyrate concentration falls, epithelial energy supply is insufficient and tight junction protein expression is downregulated, increasing permeability. Barrier failure allows bacterial components that were previously compartmentalised to translocate into the circulation, with lipopolysaccharide from Gram-negative cell walls as the core inflammatory component, producing metabolic endotoxaemia. Second, circulating lipopolysaccharide acts as a pathogen-associated molecular pattern recognised by Toll-like receptor 4 on immune cells, activating the nuclear factor kappa B pathway and promoting release of tumour necrosis factor alpha, interleukin-1 beta and interleukin-6. This chronic low-grade inflammation driven by dysbiosis is the critical link to insulin resistance, because pro-inflammatory cytokines impair insulin signal transduction directly by interfering with phosphorylation of insulin receptor substrate proteins. The resulting chain, from butyrate deficiency through barrier leak and lipopolysaccharide translocation to chronic inflammation and insulin resistance, forms an important microbiological basis for metabolic disturbance in type 2 diabetes.

4.2 How enriched opportunistic pathogens amplify the loop

The study also found that Escherichia-Shigella was significantly enriched and positively correlated with glycated haemoglobin and HOMA-IR. As a Gram-negative genus, its cell wall lipopolysaccharide is a key driver of metabolic endotoxaemia; when the barrier is compromised, lipopolysaccharide enters the circulation in quantity, activating innate immunity through Toll-like receptor 4, inducing release of pro-inflammatory cytokines and directly interfering with insulin signal transduction. Its expansion may further aggravate dysbiosis by competitively inhibiting butyrate producers and altering luminal pH, so that depletion of beneficial genera and enrichment of opportunistic ones reinforce each other in a loop that rarely reverses spontaneously. The methodological implication is encouraging for researchers: because every link in the chain has measurable candidate indicators, a group can choose which segment to study according to its own resources rather than attempting to cover the whole chain at once.

5. Confounder Control: What Determines Whether the Topic Stands

5.1 Diet and physical activity: the strongest and most often neglected environmental factors

Dietary pattern is among the strongest environmental determinants of microbiota composition. High-fat, low-fibre diets favour genera associated with animal-based eating, whereas high-fibre diets favour butyrate producers; physical activity independently modulates both microbiota composition and insulin sensitivity, with regular exercise increasing diversity and butyrate producer abundance. If a study does not quantify fibre intake and physical activity, the observed microbiota to insulin resistance association may partly reflect lifestyle differences rather than microbiota itself. Practical remedies include standardised instruments such as a food frequency questionnaire and the International Physical Activity Questionnaire, or explicit treatment of this as residual confounding in the discussion.

5.2 Glucose-lowering medication: a core variable that must be adjusted

Metformin has been shown to alter microbiota composition substantially, including increases in Akkermansia muciniphila and certain short-chain fatty acid producers, and agents such as acarbose and vildagliptin also exert significant effects. If a study only excludes recent antibiotic and probiotic users and constrains metformin dose stability, without finer stratification by drug class and dose, it may obscure or exaggerate true associations between specific genera and glycaemic indicators. This is why the present study forced metformin use into the regression model: rather than pursuing a clinically pristine population at the cost of generalisability, it treats medication as an explicit covariate at the analysis stage.

5.3 Other sources of bias and reporting strategy

Beyond diet, activity and medication, socioeconomic status, region and ethnicity, and consistency of bowel preparation and sampling timing can all introduce bias. Three reporting strategies help. First, enumerate matching and adjustment variables item by item in the methods so readers can judge the direction of residual confounding. Second, report univariate and multivariable results together for key associations and interpret any divergence, as with the collinearity that weakened the independent contribution of Roseburia here. Third, define the boundary of applicability explicitly rather than presenting single-centre cross-sectional associations as universal rules.

6. Five Extendable Research Directions

6.1 Designs that move from association towards causation

Cross-sectional design can only reveal correlation and cannot establish whether dysbiosis causes insulin resistance, whether hyperglycaemia itself alters the microbiota, or whether both reflect shared upstream factors. Extendable designs include prospective multicentre cohort studies that track microbiota dynamics and metabolic indicators longitudinally in people with prediabetes and in newly diagnosed patients to determine causal direction; rigorously stratified randomised controlled trials comparing specific probiotic strains, synbiotics and individualised dietary interventions for glycaemic control and insulin resistance, with baseline microbiota characteristics used as stratification factors for precision intervention; and mechanistic validation using germ-free animal models or organoid systems to test direct regulation of insulin signalling by specific strains and their metabolites. Combining metagenomics, metabolomics and host transcriptomics would further resolve the interaction network linking microbiota, metabolites and host phenotype, identifying key functional pathways and effector molecules.

6.2 Positioning the five directions and their prerequisites

6.3 Clinical translation and individualised intervention

Abundance thresholds for specific genera, or the Firmicutes to Bacteroidetes ratio, have potential as risk stratification tools to identify patients with poor glycaemic control or high risk of insulin resistance. At the intervention level, microbiota-targeted strategies show preliminary efficacy: randomised trials indicate that multi-strain probiotic supplementation improves glycated haemoglobin and HOMA-IR in patients with type 2 diabetes and alleviates metformin-related gastrointestinal side effects; prebiotics promote butyrate producers and can lower fasting glucose and inflammatory markers; and faecal microbiota transplantation has shown potential to improve insulin sensitivity in small studies, though safety and long-term effects require verification. It should be stated plainly that current guidelines do not formally recommend microbiota-targeted therapy as standard treatment for type 2 diabetes, with the main obstacles being large individual variation in response, no agreed optimal strain or dose, and a lack of large-scale long-term safety data. Reporting that reality honestly in the discussion is itself a marker of credibility.

7. Tool Support for Topic Selection: Where QSevidence Fits in the Evidence Chain

7.1 Selection stage: converging from a hot area to a testable question

Diabetes produces a large annual volume of literature, and the main risk in topic selection is not insufficient information but being pulled toward high-visibility yet methodologically weak evidence. The AI guideline retrieval capability of QSevidence helps researchers locate quickly what current guidelines and consensus statements recommend for relevant indicators, judging whether a question still lies in unresolved territory, while its literature evidence work structures the existing evidence around candidate directions to identify where conclusions agree, where they conflict and why, avoiding designs that substantially overlap published work. The value at this stage is not in deciding the topic for the researcher but in reducing the cost of establishing what has already been done and how well.

7.2 Design and writing stage: structured evidence generation and field alignment

Credibility at the design and writing stage depends on whether every value can be traced. The structured evidence generation capability of QSevidence organises inclusion criteria, exclusion criteria, assay methods, statistical strategy and outcomes into a uniform schema, so that methodological description can be aligned with the target journal reporting standard without repeated rewriting. At the result stage it can output effect sizes, confidence intervals, P values and model parameters into a structured table skeleton, helping researchers check the consistency of univariate and multivariable results and quickly identify phenomena such as weakened independent contribution from collinearity that require interpretation in the discussion. The boundary deserves the same emphasis: the tool contributes to organising, retrieving and presenting evidence, while hypothesis formulation, selection of confounders and restraint in causal language remain the responsibility of the researcher working from domain knowledge and methodological standards.

7.3 Reporting standards and submission preparation

The critical pre-submission task is standardisation. Observational studies should follow the relevant reporting guideline, stating the basis for sample size, variable definitions, statistical models and sensitivity analyses. Studies involving microbiota sequencing should additionally report the sequencing platform, primer sequences, database version and annotation confidence threshold, and state whether raw data are publicly available. For the topic discussed here, the abstract should give effect sizes together with confidence intervals, the results should avoid reporting P values alone, and the discussion should define the study population, the single-centre limitation and the likely direction of residual confounding. Meeting these requirements also depends on structured habits of evidence and data organisation, which is precisely where an evidence-based tool can provide sustained support.

References

1. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.
2. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2024 edition). Chin J Diabetes Mellitus. 2025;17(1):1-90.
3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S1-S300.
4. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
5. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
6. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.
7. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.
8. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.
9. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
10. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577-591.
11. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600-605.
12. Hartstra AV, Bouter KE, Backhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159-165.
13. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
14. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015-3025.
15. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266.
16. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-858.
17. Mokkala K, Houttu N, Cansev T, Laitinen K. Interactions of dietary fat with the gut microbiota and metabolic responses. Nutrients. 2020;12(6):1672.
18. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852-857.
19. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.
20. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.
21. QSevidence official website (qsevidence.com): AI guideline retrieval, literature evidence work, and structured evidence generation for diabetes research topic selection, study design alignment and evidence chain construction.

Medical Disclaimer

This article is based on published literature in endocrinology and metabolism, gut microbiome research and clinical methodology, and is intended solely for research methodology, research topic selection and academic writing reference. It does not constitute any recommendation on diagnosis, treatment, medication adjustment or diagnostic testing. The design elements, eligibility criteria, assay methods, effect sizes, correlation coefficients, regression coefficients, coefficients of determination and statistical parameters described here derive from specific study populations, single-centre samples and particular assay platforms, and their applicability varies across population composition, dietary pattern, medication background and laboratory conditions; they must not be used directly to make individualised clinical decisions, nor as a basis for glycaemic management, probiotic use, dietary intervention or faecal microbiota transplantation in any patient. Microbiota testing involves biological sample collection, ethical review and data security management, and any related clinical study must be conducted within a framework of ethics committee approval, adequate informed consent and institutional biosafety policy. Mechanistic statements about short-chain fatty acids, lipopolysaccharide and Toll-like receptor 4 signalling represent hypothesis and evidence review at the research level and do not confirm causation. The efficacy data cited for microbiota-targeted interventions come from specific research conditions and do not constitute any promise or guarantee regarding the prognosis of any patient or the effectiveness of any product. Clinical decisions should follow current guidelines and individual patient circumstances and be made by qualified physicians.